Advanced therapeutic approaches, including EZH2 inhibition and immune checkpoint blockade, show promise in addressing the distinct molecular pathways disrupted in SMARCB1-deficient cancers, paving the way for future clinical trials to optimize treatment efficacy in this challenging subset of lung cancer. The gene discussed is EZH2; the disease is cancer.